Out of the Mouths of Bastards

Regular reader may recall earlier musings where I put words in the mouths of Pharma CEOs with regard to monopoly pricing granted by FDA in the form exclusivity for some drugs for some period of time: "here's a life saving drug; so give me all your future life's earnings". Hyperbole, a bit.

Well, here comes Shkreli, again, weighing in on the EpiPen situation:

"Mylan sort of found themselves in my shoes in the sense that they bought a company, that company had a lot of old medicines, a lot of those old medicines had old prices that weren't reflective of modern prices," Shkreli said. "Three hundred dollars, they've been raising it slowly about 15 percent every six months which is relatively slowly -- not as fast as what I did. My guess is Mylan probably thinks that they could sell this thing for $1,000 a syringe. And with, now with these news reports, they probably won't."

Mylan paid a stupid price for the rights to EpiPen, and the rest of us get to pay a stupid price. They didn't invent the device or the drug that's dispensed, they just bought in both. And, by the way, the CxO crowd at Mylan have done rather well.

Proxy filings show that from 2007 to 2015, Mylan CEO Heather Bresch's total compensation went from $2,453,456 to $18,931,068, a 671 percent increase. During the same period, the company raised EpiPen prices, with the average wholesale price going from $56.64 to $317.82, a 461 percent increase, according to data provided by Connecture.

Vote for The Donald. He'll fix the problem, since it's the fault of all those Mexican rapists Obama has let in.